LEADER 04652nam 22005655 450 001 9910298314403321 005 20200707012301.0 010 $a88-470-5313-7 024 7 $a10.1007/978-88-470-5313-7 035 $a(CKB)3710000000078087 035 $a(EBL)1592544 035 $a(SSID)ssj0001086098 035 $a(PQKBManifestationID)11631667 035 $a(PQKBTitleCode)TC0001086098 035 $a(PQKBWorkID)11056169 035 $a(PQKB)11419179 035 $a(MiAaPQ)EBC1592544 035 $a(DE-He213)978-88-470-5313-7 035 $a(PPN)176127208 035 $a(EXLCZ)993710000000078087 100 $a20131209d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAdverse Events with Biomedicines $ePrevention Through Understanding /$fby Giuseppe Tridente 205 $a1st ed. 2014. 210 1$aMilano :$cSpringer Milan :$cImprint: Springer,$d2014. 215 $a1 online resource (633 p.) 300 $aDescription based upon print version of record. 311 $a88-470-5312-9 327 $aPart I General Aspects: 1 Introduction -- 2 Adverse drug events to biomedicines -- 3 Systemic syndromes caused by biomedicines -- Part II Monoclonal antibodies: 4 Monoclonal antibodies -- 5 Abciximab -- 6 Adalimumab -- 7 Alemtuzumab -- 8 Basiliximab -- 9 Belimumab -- 10 Bevacizumab -- 11 Brentuximab -- 12 Canakinumab -- 13 Catumaxomab -- 14.  Certolizumab -- 15 Cetuximab -- 16 Daclizumab -- 17 Denosumab -- 18  Eculizumab -- 19 Edrecolomab -- 20 Efalizumab -- 21 Gemtuzumab -- 22 Golimumab -- 23 Ibritumomab -- 24 Infliximab -- 25 Ipilimumab -- 26 Muromonab -- 27 Natalizumab -- 28 Nimotuzumab -- 29 Ofatumumab -- 30 Omalizumab -- 31 Palivizumab -- 32 Panitumumab -- 33 Pertuzumab -- 34 Ranibizumab -- 35 Rituximab -- 36 Tocilizumab -- 37 Tositumomab -- 38 Trastuzumab -- 39 Ustekinumab -- Part III Fusion proteins: 40 Fusion proteins -- 41 Abatacept -- 42 Aflibercept -- 43 Alefacept -- 44 Belatacept -- 45 Etanercept -- 46 Rilonacept -- 47 Romiplostim -- Part IV Cytokines : 48 Cytokines -- 49 Interleukins -- 50 Denileukin-diftitox -- 51 Anakinra -- 52 Interferons -- 53 Hemopoietic stimulatory factors -- 54 Myelopoietic stimulatory factors -- 55 Thrombopoietic stimulatory factor -- 56 Pluripotent growth factors -- 57 Epidermal growth factors -- Part V Overview: 58 Biomedicines as adverse event inducers -- 59 Conclusions and perspectives. 330 $aThis monograph gathers and evaluates data on adverse events (AEs) associated specifically with those ?biomedicines? ? monoclonal antibodies, fusion proteins, and cytokines ? that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered. Electronic data sheets, downloadable from the Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. 606 $aMedicine 606 $aPharmacy 606 $aBiomedicine, general$3https://scigraph.springernature.com/ontologies/product-market-codes/B0000X 606 $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007 606 $aPharmacy$3https://scigraph.springernature.com/ontologies/product-market-codes/F00008 615 0$aMedicine. 615 0$aPharmacy. 615 14$aBiomedicine, general. 615 24$aMedicine/Public Health, general. 615 24$aPharmacy. 676 $a615.704 700 $aTridente$b Giuseppe$4aut$4http://id.loc.gov/vocabulary/relators/aut$0101335 906 $aBOOK 912 $a9910298314403321 996 $aAdverse Events with Biomedicines$92499317 997 $aUNINA